Lyell Immunopharma is a developer of curative cell-based immunotherapies for any cancer, with a focus on CAR-Ts and solid tumors.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
03/05/2020 | Series C | $493MM | $xx.xx | $250.3B | Arch Venture Partners, Foresite Capital, Milky Way Investments | |
Price per Share
$xx.xx
Shares Outstanding
42,905,042
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, Foresite Capital, Milky Way Investments
|
||||||
07/15/2019 | Series AA | $205MM | $xx.xx | $137.43B | Gsk | |
Price per Share
$xx.xx
Shares Outstanding
30,253,189
Liquidation Pref Order
2
Liquidation Pref As Multiplier
0.5x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Gsk
|
||||||
03/15/2019 | Series B | $162.15MM | $xx.xx | $117.97B | Foresite Capital, Gemini Investments | |
Price per Share
$xx.xx
Shares Outstanding
23,929,531
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Foresite Capital, Gemini Investments
|
||||||
10/10/2018 | Series A | $179.1MM | $xx.xx | $27.55B | Arch Venture Partners, Foresite Capital, Gemini Investments | |
Price per Share
$xx.xx
Shares Outstanding
97,933,475
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, Foresite Capital, Gemini Investments
|